Leukemia in Generaldoi:10.5222/j.child.2012.153Anak, SemaUysalol, EzgiSpringer USEncyclopedia of Child Behavior & DevelopmentAcute Myelogenous Leukemia With PIG-A Gene Mutation Evolved from Aplastic Anemia—Paroxysmal Nocturnal Hemoglobinuria Syndrome[J] . Hideo Tanaka,Nobutaka Imamura,Nobuo Oguma,Takahiro...
... Acute myelogenous leukemia AML 急性骨髓细胞性白血病 Adenocarcinoma …bbs.xctmr.com|基于3个网页 2. 急性白血病 急性白血病(acute myelogenous leukemia AML)和慢性白血病(chronic myelogenous leukemia CML)时相关蛋白质受损。 …www.chemdrug.com|基于1 个网页 3. 急性髓性白血病 ...phocytic leukemia ANLL...
Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development.,站酷海洛,一站式正版视觉内容平台,站酷旗下品牌.授权内容包含正版商业图片、艺术插画、矢量、视频、音乐
Acute myelogenous leukemia (FAB AML-M1) in the setting of HIV infection and G-CSF therapy.A case report and review of the literature[J].{H}Annals of Hematology,1998.69-73.Acute myelogenous leukemia (FAB AML-M1) in the setting of HIV infection and G-CSF therapy: a case report and ...
Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects. Klin. Wschr. 61,947(1983)... D Urbanitz,T Büchner,H Pielken,... - 《Klinische Wochenschrift》 被引量: 13发表: 1983年 Bone marrow transplantation for chronic myelogenous leukemia: so...
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT...
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor [118]. Phase I study (NCT02319369) (Table1) evaluated the safety, tolerability and pharmacokinetics of milademetan alone and with 5-azacitidine in acute myelogenous leukemia (AML) or high-risk myelodysplastic ...
Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable ba... The CLASSIC II trial has previously reported an independently ...
The development of acute myelogenous leukemia (AML), which is characterized by a block of myeloid differentiation, is a multi-step process that involves several genetic abnormalities, but the molecular mechanisms by which these genetic alterations cooperate in leukemogenesis are poorly understood. The hu...
Gene alterations accumulate during the progression of acute myelogenous leukemia (AML) to a malignant clone. Here, a new myeloid cell line, designated YSK-21, with the balanced t(8;21)(q22;q22) and the unbalanced der(1)t(1;17)(p36;q21), was established. YSK-21 grows well in a mediu...